Researchers have shown that vascular endothelial growth factor A (VEGFA) protein leads to inflammation and airway obstruction related to asthma, according to a study conducted on March 7, 2018.
The Haczku lab in collaboration with Qi Yang, co-senior author of the new study had previously discovered that group 2 innate lymphoid cells (ILC2s) help in driving airway hyper responsiveness. This happens when lungs respond to allergens or toxic air pollutants. Then, the full blown asthma attack begins within the person. Researchers were not able to find the cause for airway obstruction. To find a solution to this problem, they observed the response of a mouse model to a common allergen, Alternaria alternata. Within few hours, the airways was infiltrated by the immune cells and inflammation was generated. When mice was treated using VEGFA inhibitor SU1498, a declination in both immune response and inflammation was observed.
Although VEGFA is known for its activity in cancer and growing blood vessels to help in feeding tumors, this research outlines a different role of VEGFA in asthma. New asthma treatments could be developed by illuminating this biology. Glucocorticoid inhalers were the go-to treatment in the past and monoclonal antibodies are being used in the recent past to hit more precise targets. These antibodies are capable of targeting specific molecules.
Yang said, “These ILCs produce an influx of inflammatory neutrophils into the lungs, and we do not know exactly what mediates this cellular inflammation.” The research team is still interrogating ILC2s that could be important in other lung conditions. This study will be beneficial in developing new drugs for the treatment of asthma and therefore, will increase the growth of allergy diagnostic and treatment market, as elaborated in the Allergy Diagnostic And Treatment Market report published by Coherent Market Insights.